1042P - Thromboembolic events in french breast and prostate cancer patients hospitalized in 2011 and 2012: incidence and costs

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Supportive Care
Bioethics, Legal, and Economic Issues
Breast Cancer
Prostate Cancer
Presenter Florian Scotte
Citation Annals of Oncology (2014) 25 (suppl_4): iv357-iv360. 10.1093/annonc/mdu341
Authors F. Scotte1, A. Vainchtock2, I. Borget3, N. Martelli4
  • 1Medical Oncology And Supportive Cancer Care Unit, Hospital G.Pompidou and Rene Descartes University, 75015 - Paris/FR
  • 2Health Economy, HEVA, Lyon/FR
  • 3Biostatistics And Epidemiology, institut Gustave Roussy, 94805 - Villejuif/FR
  • 4Pharmacy, Hôpital Européen Georges Pompidou (HEGP), Paris/FR

View Poster

Abstract

Aim

Venous thromboembolic event (VTE) is a common complication for cancer patients, leading to hospitalizations that increase the burden of cancer management. We evaluated the incidence and costs of VTE-related hospitalizations for patients with breast cancer (BC) or prostate cancer (PC), two of the most frequent cancers in France.

Methods

We used the French national hospital database (PMSI) to select new patients with BC or PC in 2010, who had at least one VTE-related hospitalization during the following two years. VTE-related stays and patients were identified using the disease-specific ICD-10 codes. Hospital costs were estimated from the healthcare system perspective and included care, treatments, accommodation/investment costs and medical/technical procedures, using the French official tariffs.

Results

Among 107,916 new patients with BC or PC, 2,268 were hospitalized for a VTE, representing an overall of 2,814 admissions. VTE was classified as primary or related diagnosis (PD/RD) in 1,004 (36%) admissions. Among those PD/RD admissions, pulmonary embolism was the most frequent diagnosis as it led to 626 (62%) stays. Deep venous thrombosis was the second cause of hospitalization (248 admissions; 25% of PD/RD admissions). Re-hospitalisation for recurrence was frequent, as it occurred 546 cases (19.4%) of all VTE-related hospitalizations. For a patient who did not experience recurrence, the mean cost per patient was €3,302 and €3,611 for BC and PC patients respectively. But this annual amount was highly increased for patients with recurrent VTE, to €5,545 per BC patient and €5,692 per PC patient. Finally, VTE-related hospitalizations were responsible for an overall expenditure of €3.40 million over two years, including €335,000 due to recurrent events.

Table: Mean annual VTE-related hospitalization cost per patient.

With one
VTE only		 With
recurrent VTE
Annual cost per breast cancer patient €3,302 €5,545
Annual cost per prostate cancer patient €3,611 €5,692

Conclusions

In cancer patients, VTE-related hospitalizations remain frequent and induce an elevated cost. Adequate prophylaxis and management could be an efficient way to reduce the incidence of this common complication and its economic burden.

Disclosure

F. Scotte, I. Borget and N. Martelli: I have honoraria from Leo Pharma. All other authors have declared no conflicts of interest.